LOAMU
TVTX icon

Lombard Odier Asset Management (USA)’s Travere Therapeutics TVTX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100,000
Closed -$1.78M – 285
2016
Q2 		$1.78M Buy
+100,000
New +$1.62M 0.22% 116

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s TVTX Position: Q3 2020 in Review

Lombard Odier Asset Management (USA) sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 150,000 shares — an estimated $3.06M sold.

Lombard Odier Asset Management (USA) first reported a position in TVTX in Q1 2014 and held it in 26 quarters. The position peaked at $48M in Q1 2015. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Lombard Odier Asset Management (USA) reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 150,000 Travere Therapeutics shares in Q3 2020, an estimated $3.06M.
  • Lombard Odier Asset Management (USA) first reported a position in Travere Therapeutics in Q1 2014 and held it in 26 quarters.
  • Lombard Odier Asset Management (USA)'s Travere Therapeutics position peaked at $48M in Q1 2015.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2020, filed 16 Nov 2020.